Invited oral presentation includes in vivo proof-of-concept data for AI-identified targeted therapies to be incorporated into ADCs to treat early-stage lung adenocarcinoma.
CAMBRIDGE, MA / ACCESS Newswire / April 24, 2025 / Archetype Therapeutics, a drug discovery company that uses generative AI to rapidly screen billions of potential drugs virtually for their clinical impact in genomically-defined patient cohorts, announced today an upcoming oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois.
The presentation will showcase in vitro and in vivo (GEMM and xenograft) validation data on novel and repurposed small molecules identified by the Archetype™ platform, in collaboration with Dr. Charles A. Powell's lab at the Icahn School of Medicine at Mount Sinai. It will highlight the ability of Archetype molecules to intercept invasion in lung adenocarcinoma, comparing their effectiveness to previously published molecules. By targeting invasive lung cancer, these molecules can prevent metastasis. Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.
"Several months ago, we set out to validate molecular candidates discovered by the Archetype platform utilizing our published early-stage lung adenocarcinoma experimental protocols," said Dr. Powell. "We are excited to present the results at AACR, demonstrating that these candidates include small molecules that are effective and substantially outperform those previously identified using other approaches."
To identify novel and repurposed drugs for patients with unmet need, Archetype utilizes a combination of generative chemogenomics to produce the expected changes in biology that small molecules will induce - without prior lab testing - and patient clinicogenomic classifiers, such as those sold by diagnostic companies, to predict the drugs' clinical impact given such changes in biology.
"Archetype has demonstrated that we can advance from initiating an AI-driven research program to identifying molecules with compelling in vivo proof of concept data in just months and in a highly cost-efficient manner," said Tom Neyarapally, CEO and Co-Founder of Archetype Therapeutics. "We are excited about addressing unmet patient need in lung cancer by developing both ADCs with Abzena and Alloy Therapeutics utilizing targeted payloads, and developing standalone novel small molecules."
Abstract Number: 1139
Title: Massive scale phenotypic screening using Generative Chemogenomics repurposes safe drugs and discovers new drugs for intercepting early-stage lung adenocarcinoma progression
Presenting Author: Dr. Abhilasha Sinha, Assistant Professor, Icahn School of Medicine at Mount Sinai
Session Title: Minisymposia
Session Date and Time: Sunday, April 27, 2025, 3:20-3:35pm CDT
Location: Room S103 - McCormick Place South (Level 1), McCormick Place Convention Center, Chicago, IL
The abstract will be published in the online ‘Proceedings of the AACR.'
About Archetype
Archetype Therapeutics is an AI-native biotech that is pioneering the use of AI for generative chemogenomics - enabling the virtual screening of billions of potential drugs per day in genomically-defined patient cohorts. The disease-agnostic Archetype platform has been deployed and validated in in vitro and in vivo testing in early-stage lung adenocarcinoma (esLUAD), metastatic castration-resistant prostate cancer (mCRPC), and other diseases, and has accurately predicted the outcomes of clinical trials and the impact of drugs in these diseases. Archetype is partnering across the healthcare and life sciences ecosystem to rapidly discover and develop patient-driven therapeutics.
Please contact Tom Neyarapally at tom@archetypetx.com to discuss how to partner with Archetype on our mission to rapidly discover and develop therapies for underserved patients.
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City's large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master's degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics.
Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
SOURCE: Archetype Therapeutics
View the original press release on ACCESS Newswire
